CNSY

CERENOME, INC.
—

Company Information

Company Name
CERENOME, INC.
CIK
CIK0001095981
Category
Non-accelerated filer<br>Smaller reporting company
Ticker: Exchange
CNSY: Nasdaq
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2834
SIC Description
Pharmaceutical Preparations
Ticker
CNSY

SEC filing data through

Insider Sentiment

Last purchase
2025-11-04
Last sale
2023-11-20
Shares purchased (TTM)
130,000
Shares sold (TTM)
0
Buy ratio (TTM)100.0%

Institutional Sentiment

As of
2026-06-30
Institutional shares owned
603,184
Shares outstanding
6,898,804
Ownership
8.74%
-10.79% Y/Y

Earnings Market Reaction

Filing date
2026-11-13
Price on filing date
—
1-month reaction
…
3-month reaction
…
Drift continued3/9 (33%)
Faded / reversed6/9 (67%)

Balance Sheet

Values in millions ($)
Line item2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Assets Current
Cash And Cash Equivalents At Carrying Value12341321001539
Restricted Cash And Cash Equivalents At Carrying Value---5--------
Short Term Investments4612435-4440-
Grants Receivable Current-210-1-1----
Other Assets Current212211111111
Assets Current812181518911559410
Property Plant And Equipment Net111000001111
Operating Lease Right Of Use Asset000000000000
Goodwill000000000000
Other Intangible Assets Net000000001100
Other Assets Noncurrent000000000000
Assets121420161910127711611
Liabilities Current
Accounts Payable And Accrued Liabilities Current88661269118767
Operating Lease Liability Current000000000000
Deferred Income Current11112111120-
Long Term Debt Current----------44
Lines Of Credit Current0011---333--
Other Liabilities Current0000--------
Liabilities Current139812147111612191011
Operating Lease Liability Noncurrent---0---00000
Deferred Income Noncurrent-----------2
Liabilities139812147361612191013
Common Stock Value000000000000
Treasury Stock Common Value-1-1-1-1-1-1-1-1-1-1-1-0
Additional Paid In Capital540538535520516509488485485480479479
Retained Earnings Accumulated Deficit-540-532-523-516-510-506-511-493-490-487-484-481
Stockholders Equity-1512453-24-9-5-8-5-1
Liabilities And Stockholders Equity121420161910127711611
Stockholders Equity
Preferred Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Preferred Stock Shares Authorized555555555555
Preferred Stock Shares Issued000000000000
Preferred Stock Shares Outstanding000000000000
Common Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Common Stock Shares Authorized2,0002,0002,0002,0002,0002,000100100100100100100
Common Stock Shares Issued877654100000
Shares Outstanding877654100000
Treasury Stock Common Shares000000000000

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

CERENOME, INC. (CNSY) — SEC Financial Statements & Analysis

CERENOME, INC. (CNSY) is a pharmaceutical preparations company, incorporated in DE. CERENOME, INC. trades on Nasdaq as: CNSY. CERENOME, INC. (CNSY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-13. Based on that filing, CERENOME, INC. carries a market cap of $14.15M, a P/E ratio of -0.47x, a P/B ratio of -15.33x, a P/S ratio of 4.01x, an enterprise value of $13.27M, and an EV/EBITDA multiple of -0.46x. On profitability, it posts a gross margin of 103.81%, an operating margin of -832.57%, a net margin of -859.47%, a Return on Equity (ROE) of -1468.02%, a Return on Assets (ROA) of -196.45%, and a Return on Invested Capital (ROIC) of -1291.46%. Per share, it reports EPS of $-4.01, diluted EPS of $-4.01, free cash flow per share of $-3.79, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -32.90% year-over-year, net income growth of 47.37% year-over-year, and EPS growth of -16.31% year-over-year. On the balance sheet, it maintains a current ratio of 0.61x, a quick ratio of 0.61x, working capital of $-5.06M, a debt-to-equity ratio of -14.22x, a debt ratio of 1.08, an interest coverage ratio of -815.92x, free cash flow of $-28.70M (TTM), and net debt of $-879.00K. Figures sourced from SEC EDGAR.

Market Cap
$14.15M
P/E TTM
-0.47x
EPS TTM
$-4.01
P/B TTM
-15.33x
ROE TTM
-1468.02%
ROA TTM
-196.45%
Debt To Equity
-14.22x
Free Cash Flow TTM
$-28.70M
Net Revenue TTM Growth 1Y
-32.90%

Data as of 2026-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CERENOME, INC. in?

CERENOME, INC. (CNSY) operates in the Pharmaceutical Preparations industry.

What exchange does CNSY trade on?

CERENOME, INC. (CNSY) trades on the Nasdaq.

Where is CERENOME, INC. incorporated?

CERENOME, INC. is incorporated in DE.

When was CERENOME, INC. (CNSY)'s most recent SEC filing?

CERENOME, INC. (CNSY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-13.

What is CNSY's market cap?

CERENOME, INC. (CNSY) has a market capitalization of $14.15M as of 2026-09-30.

What is CNSY's EPS (earnings per share)?

CERENOME, INC. (CNSY)'s trailing twelve month EPS is $-4.01 as of 2026-09-30.

What is CNSY's ROE (return on equity)?

CERENOME, INC. (CNSY)'s trailing twelve month Return on Equity (ROE) is -1468.02% as of 2026-09-30.

What is CNSY's ROA (return on assets)?

CERENOME, INC. (CNSY)'s trailing twelve month Return on Assets (ROA) is -196.45% as of 2026-09-30.

What is CNSY's ROIC (return on invested capital)?

CERENOME, INC. (CNSY)'s trailing twelve month Return on Invested Capital (ROIC) is -1291.46% as of 2026-06-30.

What is CNSY's EV/EBITDA?

CERENOME, INC. (CNSY)'s trailing twelve month EV/EBITDA is -0.46x as of 2026-09-30.

Wall Street's data.
Main Street's price.